(Q34284691)

1 August 2017

title

Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis (English)

1 reference

1 August 2017

1 reference

systemic mastocytosis

1 reference

2

Hagop M Kantarjian

1 reference

1 August 2017

5

Srdan Verstovsek

1 reference

1 August 2017

4

Jorge E Cortes

1 reference

1 August 2017

1

Sameer A Parikh

1 reference

1 August 2017

3

Mary Ann Richie

1 reference

1 August 2017

publication date

1 February 2010

1 reference

1 August 2017

1 reference

1 August 2017

volume

51

1 reference

1 August 2017

issue

2

1 reference

1 August 2017

page(s)

269-274

1 reference

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors

1 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184061

Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184061

Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184061

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184061

Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184061

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184061

Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184061

Imatinib mesylate in the treatment of hematologic malignancies

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184061

Mastocytosis: state of the art.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184061

Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184061

Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184061

Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184061

Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184061

Diagnostic criteria and classification of mastocytosis: a consensus proposal

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184061

c-Kit and c-kit mutations in mastocytosis and other hematological diseases.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184061

Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells.

6 July 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903486220

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903486220

Intraperitoneal chemotherapy for ovarian cancer: overview and perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903486220

Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903486220

Imatinib for systemic mast-cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903486220

Dasatinib therapy for systemic mastocytosis: four cases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903486220

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903486220

10.3109/10428190903486220

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference

1 August 2017

1 reference